EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Hoffmann-La Roche200 enrolled

Overview

The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Rheumatoid Arthritis

Interventions

TocilizumabBIOLOGICAL

Subcutaneous Tocilizumab according to approved label.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Aged \>/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to approved label within 4 weeks prior to enrolment. Exclusion Criteria: * Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to enrolment. * Participants who have received TCZ in past treatments. * Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) of starting treatment TCZ SC. * Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).

Locations (26)

Private Practice Rheumatology, Merantzis

Agrinio, Greece

Outcomes

Primary Outcomes

Percentage of Participants Still Receiving Subcutaneous Tocilizumab Therapy at 52 Weeks of Observation

Time frame: At 52 weeks